These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 27055866)

  • 1. Activity of 8F4, a T-cell receptor-like anti-PR1/HLA-A2 antibody, against primary human AML in vivo.
    Sergeeva A; He H; Ruisaard K; St John L; Alatrash G; Clise-Dwyer K; Li D; Patenia R; Hong R; Sukhumalchandra P; You MJ; Gagea M; Ma Q; Molldrem JJ
    Leukemia; 2016 Jul; 30(7):1475-84. PubMed ID: 27055866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells.
    Ma Q; Garber HR; Lu S; He H; Tallis E; Ding X; Sergeeva A; Wood MS; Dotti G; Salvado B; Ruisaard K; Clise-Dwyer K; John LS; Rezvani K; Alatrash G; Shpall EJ; Molldrem JJ
    Cytotherapy; 2016 Aug; 18(8):985-994. PubMed ID: 27265873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An anti-PR1/HLA-A2 T-cell receptor-like antibody mediates complement-dependent cytotoxicity against acute myeloid leukemia progenitor cells.
    Sergeeva A; Alatrash G; He H; Ruisaard K; Lu S; Wygant J; McIntyre BW; Ma Q; Li D; St John L; Clise-Dwyer K; Molldrem JJ
    Blood; 2011 Apr; 117(16):4262-72. PubMed ID: 21296998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Novel T-Cell Engaging Bi-specific Antibody Targeting the Leukemia Antigen PR1/HLA-A2.
    Herrmann AC; Im JS; Pareek S; Ruiz-Vasquez W; Lu S; Sergeeva A; Mehrens J; He H; Alatrash G; Sukhumalchandra P; St John L; Clise-Dwyer K; Zha D; Molldrem JJ
    Front Immunol; 2018; 9():3153. PubMed ID: 30713535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adoptive transfer of PR1 cytotoxic T lymphocytes associated with reduced leukemia burden in a mouse acute myeloid leukemia xenograft model.
    Ma Q; Wang C; Jones D; Quintanilla KE; Li D; Wang Y; Wieder ED; Clise-Dwyer K; Alatrash G; Mj Y; Munsell MF; Lu S; Qazilbash MH; Molldrem JJ
    Cytotherapy; 2010 Dec; 12(8):1056-62. PubMed ID: 20735170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Broad cross-presentation of the hematopoietically derived PR1 antigen on solid tumors leads to susceptibility to PR1-targeted immunotherapy.
    Alatrash G; Mittendorf EA; Sergeeva A; Sukhumalchandra P; Qiao N; Zhang M; St John LS; Ruisaard K; Haugen CE; Al-Atrache Z; Jakher H; Philips AV; Ding X; Chen JQ; Wu Y; Patenia RS; Bernatchez C; Vence LM; Radvanyi LG; Hwu P; Clise-Dwyer K; Ma Q; Lu S; Molldrem JJ
    J Immunol; 2012 Dec; 189(11):5476-84. PubMed ID: 23105141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells.
    Jin L; Lee EM; Ramshaw HS; Busfield SJ; Peoppl AG; Wilkinson L; Guthridge MA; Thomas D; Barry EF; Boyd A; Gearing DP; Vairo G; Lopez AF; Dick JE; Lock RB
    Cell Stem Cell; 2009 Jul; 5(1):31-42. PubMed ID: 19570512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors.
    Feuring-Buske M; Frankel AE; Alexander RL; Gerhard B; Hogge DE
    Cancer Res; 2002 Mar; 62(6):1730-6. PubMed ID: 11912147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-individualized CD8⁺ cytolytic T-cell therapy effectively combats minimal residual leukemia in immunodeficient mice.
    Distler E; Albrecht J; Brunk A; Khan S; Schnürer E; Frey M; Mottok A; Jordán-Garrote AL; Brede C; Beilhack A; Mades A; Tomsitz D; Theobald M; Herr W; Hartwig UF
    Int J Cancer; 2016 Mar; 138(5):1256-68. PubMed ID: 26376181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-27 inhibits the growth of pediatric acute myeloid leukemia in NOD/SCID/Il2rg-/- mice.
    Zorzoli A; Di Carlo E; Cocco C; Ognio E; Ribatti D; Ferretti E; Dufour C; Locatelli F; Montagna D; Airoldi I
    Clin Cancer Res; 2012 Mar; 18(6):1630-40. PubMed ID: 22383738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia.
    Molldrem JJ; Lee PP; Wang C; Champlin RE; Davis MM
    Cancer Res; 1999 Jun; 59(11):2675-81. PubMed ID: 10363991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody-based delivery of interleukin-2 to neovasculature has potent activity against acute myeloid leukemia.
    Gutbrodt KL; Schliemann C; Giovannoni L; Frey K; Pabst T; Klapper W; Berdel WE; Neri D
    Sci Transl Med; 2013 Sep; 5(201):201ra118. PubMed ID: 24005158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia.
    van der Lee DI; Reijmers RM; Honders MW; Hagedoorn RS; de Jong RC; Kester MG; van der Steen DM; de Ru AH; Kweekel C; Bijen HM; Jedema I; Veelken H; van Veelen PA; Heemskerk MH; Falkenburg JHF; Griffioen M
    J Clin Invest; 2019 Feb; 129(2):774-785. PubMed ID: 30640174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Auger electron radioimmunotherapeutic agent specific for the CD123+/CD131- phenotype of the leukemia stem cell population.
    Leyton JV; Hu M; Gao C; Turner PV; Dick JE; Minden M; Reilly RM
    J Nucl Med; 2011 Sep; 52(9):1465-73. PubMed ID: 21816968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute myeloid leukemia (AML)-reactive cytotoxic T lymphocyte clones rapidly expanded from CD8(+) CD62L((high)+) T cells of healthy donors prevent AML engraftment in NOD/SCID IL2Rgamma(null) mice.
    Distler E; Wölfel C; Köhler S; Nonn M; Kaus N; Schnürer E; Meyer RG; Wehler TC; Huber C; Wölfel T; Hartwig UF; Herr W
    Exp Hematol; 2008 Apr; 36(4):451-63. PubMed ID: 18261837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel myeloperoxidase-derived HLA-A2-restricted peptides as therapeutic targets against myeloid leukemia.
    Lu S; Tallis E; Ding X; Li D; Cox K; You MJ; St John L; Alatrash G; Ma Q; Molldrem JJ
    Cytotherapy; 2021 Sep; 23(9):793-798. PubMed ID: 34215503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia.
    Ågerstam H; Karlsson C; Hansen N; Sandén C; Askmyr M; von Palffy S; Högberg C; Rissler M; Wunderlich M; Juliusson G; Richter J; Sjöström K; Bhatia R; Mulloy JC; Järås M; Fioretos T
    Proc Natl Acad Sci U S A; 2015 Aug; 112(34):10786-91. PubMed ID: 26261316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon-γ Promotes Antibody-mediated Fratricide of Acute Myeloid Leukemia Cells.
    Fatehchand K; McMichael EL; Reader BF; Fang H; Santhanam R; Gautam S; Elavazhagan S; Mehta P; Buteyn NJ; Merchand-Reyes G; Vasu S; Mo X; Benson DM; Blachly JS; Carson WE; Byrd JC; Butchar JP; Tridandapani S
    J Biol Chem; 2016 Dec; 291(49):25656-25666. PubMed ID: 27780867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effectiveness of anti-CD47 antibody and Ara-C combination targeting therapy NOD/SCID mouse of myeloid leukemia].
    Wang YC; Feng L; Yin CY; Ma LN; Wei YW; Wang CM; Sheng GY
    Zhongguo Dang Dai Er Ke Za Zhi; 2013 Jul; 15(7):577-82. PubMed ID: 23866283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells.
    Kikushige Y; Shima T; Takayanagi S; Urata S; Miyamoto T; Iwasaki H; Takenaka K; Teshima T; Tanaka T; Inagaki Y; Akashi K
    Cell Stem Cell; 2010 Dec; 7(6):708-17. PubMed ID: 21112565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.